Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6758-6765

  Moon, Seong Mi ^a   Park, Hye Yun ^a   Kim, Su Young ^a   Jhun, Byung Woo ^a   Lee, Hyun ^a   Jeon, Kyeongman ^a   Kim, Dae Hun ^a   Huh, Hee Jae ^a   Ki, Chang Seok ^a   Lee, Nam Yong ^a   Kim, Hong Kwan ^a   Choi, Yong Soo ^a   Kim, Jhingook ^a   Lee, Seung Heon ^b   Kim, Chang Ki ^b   Shin, Sung Jae ^c   Daley, Charles L ^d   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korean Institute of Tuberculosis   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; MACROLIDE; MOXIFLOXACIN; RIFABUTIN; RIFAMYCIN; RNA 23S; STREPTOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HUMAN; LUNG INFECTION; MALE; MONOTHERAPY; MORTALITY RATE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; BACTERIAL GENE; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MUTATION; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; FEMALE; GENE EXPRESSION; GENES, BACTERIAL; HUMANS; LUNG; MACROLIDES; MALE; MIDDLE AGED; MUTATION; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; RIFAMPIN; RNA, RIBOSOMAL, 23S; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84994885760     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01240-16     Document Type: Article

References (49)

1. Prevots DR, Marras TK. 2015. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin Chest Med 36: 13-34. http://dx.doi.org/10.1016/j.ccm.2014.10.002.
2. Stout JE, Koh WJ, Yew WW. 2016. Update on pulmonary disease due to non-Tuberculous mycobacteria. Int J Infect Dis 45:123-134. http://dx.doi.org/10.1016/j.ijid.2016.03.006.
3. van Ingen J, Ferro BE, Hoefsloot W, Boeree MJ, van Soolingen D. 2013. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: The evidence. Expert Rev Anti Infect Ther 11:1065-1077. http://dx.doi.org/10.1586/14787210.2013.830413.
4. Philley JV, Griffith DE. 2015. Treatment of slowly growing mycobacteria. Clin Chest Med 36:79-90. http://dx.doi.org/10.1016/j.ccm.2014.10.005.
5. Ryu YJ, Koh WJ, Daley CL. 2016. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc Respir Dis (Seoul) 79:74-84. http://dx.doi.org/10.4046/trd.2016.79.2.74.
6. Kang YA, Koh WJ. 2016. Antibiotic treatment for nontuberculous mycobacterial lung disease. Expert Rev Respir Med 10:557-568. http://dx.doi.org/10.1586/17476348.2016.1165611.
7. Kwon YS, Koh WJ. 2016. Diagnosis and treatment of nontuberculous mycobacterial lung disease. J Korean Med Sci 31:649-659. http://dx.doi.org/10.3346/jkms.2016.31.5.649.
8. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. 1999. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 160:866-872. http://dx.doi.org/10.1164/ajrccm.160.3.9811086.
9. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 12:195-202. http://dx.doi.org/10.1007/s10156-006-0457-8.
10. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. 2012. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 18: 436-443. http://dx.doi.org/10.1007/s10156-011-0351-x.
11. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. 2012. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 15:149-161. http://dx.doi.org/10.1016/j.drup.2012.04.001.
12. Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE, Wolfe CR, Turenne CY, Wallace RJ, Jr. 2013. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 51:3389-3394. http://dx.doi.org/10.1128/JCM.01612-13.
13. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367-416. http://dx.doi.org/10.1164/rccm.200604-571ST.
14. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ, Jr. 2006. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 174:928-934. http://dx.doi.org/10.1164/rccm.200603-450OC.
15. Kadota T, Matsui H, Hirose T, Suzuki J, Saito M, Akaba T, Kobayashi K, Akashi S, Kawashima M, Tamura A, Nagai H, Akagawa S, Kobayashi N, Ohta K. 2016. Analysis of drug treatment outcome in clarithromycinresistant Mycobacterium avium complex lung disease. BMC Infect Dis 16: http://dx.doi.org/10.1186/s12879-016-1384-7.
16. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. 2006. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 129:341-348. http://dx.doi.org/10.1378/chest.129.2.341.
17. Sim YS, Park HY, Jeon K, Suh GY, Kwon OJ, Koh WJ. 2010. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med J 51:888-894. http://dx.doi.org/10.3349/ymj.2010.51.6.888.
18. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, Shin SJ, Kwon OJ. 2012. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease. Chest 142:1482-1488. http://dx.doi.org/10.1378/chest.12-0494.
19. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, Ki CS, Lee NY, Shin SJ, Daley CL, Koh WJ. 2015. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 191:96-103. http://dx.doi.org/10.1164/rccm.201408-1545OC.
20. Wang HY, Bang H, Kim S, Koh WJ, Lee H. 2014. Identification of Mycobacterium species in direct respiratory specimens using reverse blot hybridisation assay. Int J Tuberc Lung Dis 18:1114-1120. http://dx.doi.org/10.5588/ijtld.14.0140.
21. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Jamal MA, Maeda S, Nakata N, Kai M, Fukuchi K, Kashiwabara Y. 2000. Molecular basis of clarithromycin-resistance in Mycobacterium avium-intracellulare complex. Tuber Lung Dis 80:1-4. http://dx.doi.org/10.1054/tuld.1999.0227.
23. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ. 2011. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:405-410. http://dx.doi.org/10.1164/rccm.201003-0395OC.
24. Koh WJ, Jeong BH, Jeon K, Kim SY, Park KU, Park HY, Huh HJ, Ki CS, Lee NY, Lee SH, Kim CK, Daley CL, Shin SJ, Kim H, Kwon OJ. 7 May 2016. Oral macrolide therapy following short-Term combination antibiotic treatment for Mycobacterium massiliense lung disease. Chest. http://dx.doi.org/10.1016/j.chest.2016.05.003.
25. Wallace RJ, Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH. 1994. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.Am J Respir Crit Care Med 149:1335-1341. http://dx.doi.org/10.1164/ajrccm.149.5.8173775.
26. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ, Jr. 1996. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 23:983-989. http://dx.doi.org/10.1093/clinids/23.5.983.
27. Wallace RJ, Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. 1996. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.AmJ Respir Crit Care Med 153:1766-1772. http://dx.doi.org/10.1164/ajrccm.153.6.8665032.
28. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, Dezfuli MG, Bozzette SA, Bartok AE, Leedom JM, Tilles JG, Mc-Cutchan JA. 1997. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 176:1225-1232.
29. Nash KA. 2001. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother 45: 1607-1614. http://dx.doi.org/10.1128/AAC.45.6.1607-1614.2001.
30. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ, Jr. 2005. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 172:250-253. http://dx.doi.org/10.1164/rccm.200407-863OC.
31. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. 2012. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.AmJ Respir Crit Care Med 186:559-565. http://dx.doi.org/10.1164/rccm.201204-0682OC.
32. Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ. 2012. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 186:797-802. http://dx.doi.org/10.1164/rccm.201206-1088OC.
33. Kwon YS, Koh WJ. 2014. Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea. Tuberc Respir Dis (Seoul) 77:1-5. http://dx.doi.org/10.4046/trd.2014.77.1.1.
34. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. 2005. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol 43:4407-4412. http://dx.doi.org/10.1128/JCM.43.9.4407-4412.2005.
35. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. 2012. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 185:575-583. http://dx.doi.org/10.1164/rccm.201107-1203OC.
36. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H, Muro S, Niimi A, Mishima M. 2012. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 16:408-414. http://dx.doi.org/10.5588/ijtld.11.0148.
37. Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. 2015. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open 5:e008058. http://dx.doi.org/10.1136/bmjopen-2015-008058.
38. Koh WJ, Hong G, Kim SY, Jeong BH, Park HY, Jeon K, Kwon OJ, Lee SH, Kim CK, Shin SJ. 2013. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother 57:2281-2285. http://dx.doi.org/10.1128/AAC.02281-12.
39. Jo KW, Kim S, Lee JY, Lee SD, Kim WS, Kim DS, Shim TS. 2014. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother 20:602-606. http://dx.doi.org/10.1016/j.jiac.2014.05.010.
40. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. 2016. Long-Term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 149: 1285-1293. http://dx.doi.org/10.1378/chest.15-0543.
41. Kang HK, Park HY, Kim D, Jeong BH, Jeon K, Cho JH, Kim HK, Choi YS, Kim J, Koh WJ. 2015. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis 15:76. http://dx.doi.org/10.1186/s12879-015-0823-1.
42. Mitchell JD. 2015. Surgical approach to pulmonary nontuberculous my-cobacterial infections. Clin Chest Med 36:117-122. http://dx.doi.org/10.1016/j.ccm.2014.11.004.
43. Nash KA, Inderlied CB. 1995. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 39:2625-2630. http://dx.doi.org/10.1128/AAC.39.12.2625.
44. Meier A, Heifets L, Wallace RJ, Jr, Zhang Y, Brown BA, Sander P, Bottger EC. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 174:354-360. http://dx.doi.org/10.1093/infdis/174.2.354.
45. Christianson S, Grierson W, Wolfe J, Sharma MK. 2013. Rapid molecular detection of macrolide resistance in the Mycobacterium avium complex: Are we there yet? J Clin Microbiol 51:2425-2426. http://dx.doi.org/10.1128/JCM.00555-13.
46. Hirama T, Shiono A, Egashira H, Kishi E, Hagiwara K, Nakamura H, Kanazawa M, Nagata M. 2016. PCR-based rapid identification system using bridged Nucleic acids for detection of clarithromycin-resistant Mycobacterium avium-M. intracellulare complex isolates. J Clin Microbiol 54:699-704. http://dx.doi.org/10.1128/JCM.02954-15.
47. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 56:4806-4815. http://dx.doi.org/10.1128/AAC.05546-11.
48. Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, Suda T, Hayakawa H. 2014. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 11:23-29. http://dx.doi.org/10.1513/AnnalsATS.201308-266OC.
49. Wallace RJ, Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. 2014. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 146:276-282. http://dx.doi.org/10.1378/chest.13-2538.